American Well Corporation reports developments for Amwell, a SaaS-based software platform for technology-enabled healthcare used by payers and health systems. Company updates center on quarterly and annual operating results, business reviews, investor conference participation, and equity-compensation actions such as inducement-plan grants.
The Amwell platform combines software and services that support virtual care programs across the care continuum, including virtual primary care, urgent care, clinical partner programs, scheduling, provider workflows, prescribing, and treatment-guideline reference tools. News about AMWL commonly connects these platform capabilities with payer and health system relationships, partner clinical programs, and management commentary on technology-enabled care delivery.
Amwell (NYSE: AMWL) has granted 3,451 Restricted Stock Units (RSUs) of Class A common stock to a new employee as an employment inducement. The vesting schedule includes 25% of RSUs vesting on the first anniversary of the grant date, with the remaining 75% vesting in equal increments every three months over the following three years. The grant was approved by Amwell's Compensation Committee under the company's Inducement Plan and complies with NYSE's Listed Company Manual Rule 303A.08.
Amwell (NYSE: AMWL), a provider of SaaS-based technology-enabled healthcare platforms, has announced its financial results for the first quarter ending March 31, 2025. The company will host a conference call on May 1, 2025, at 5 p.m. ET to discuss these results. The earnings report can be accessed through Amwell's investor relations website, and the conference call will be available via live audio webcast, with a replay accessible afterward on the investor relations site.
Amwell (NYSE: AMWL), a leading provider of SaaS-based healthcare technology platform, has announced its participation in two major upcoming investor conferences.
Key events include:
- Needham & Co. Virtual Technology and Services Conference on May 8, where CFO and COO Mark Hirschhorn will conduct one-on-one meetings virtually
- Truist Securities Healthcare Disruptors & Digital Health Conference on June 24 in New York City, featuring Mark Hirschhorn's participation
Amwell (NYSE: AMWL), a digital care leader, has scheduled its first quarter 2025 earnings release for Thursday, May 1, 2025, after market close. The company will host a conference call and webcast at 5 p.m. ET where management will discuss Q1 2025 operating results and provide business updates.
The earnings report and live audio webcast will be accessible through the Investors section of Amwell's website. A replay of the webcast will remain available at investors.amwell.com for approximately 90 days following the call.
Amwell (NYSE: AMWL) has announced a significant inducement grant to its new chief product and technology officer, Dan Zamansky. The grant consists of restricted stock units (RSUs) covering 220,844 shares of Class A common stock.
The vesting schedule includes:
- 25% vesting after six months (Initial Vesting Date)
- Remaining 75% vesting in equal increments every three months
- Full vesting occurs four years from grant date
If terminated without cause or with good reason, Zamansky's RSUs will continue vesting through the first anniversary of termination. In case of involuntary termination one month before or within 24 months after a change in control, all RSUs will immediately vest. The grant was approved under Amwell's Inducement Plan and NYSE Rule 303A.08.
Amwell (NYSE: AMWL) has appointed Dan Zamansky as its new chief product and technology officer, effective March 03, 2025. Zamansky, an Amazon veteran with over a decade of experience, will lead the company's product and R&D organizations.
At Amazon, Zamansky founded and led AWS Health AI, the company's cloud initiative focused on democratizing AI technology access for healthcare customers. He also managed product and technology teams across AWS and Amazon Ads initiatives.
In his new role, Zamansky will focus on Amwell's technology-enabled care platform for payers and health systems, ensuring its evolution to meet increasing online care demands. He succeeds Vaughn Paunovich, who has served since 2022 and led the company through a re-platforming phase.
Amwell (NYSE: AMWL) has announced the issuance of Restricted Stock Units (RSUs) to four new employees as employment inducements. The grants, approved by the company's Compensation Committee, total 16,737 shares of Class A common stock. The vesting schedule includes 25% of RSUs vesting on the first anniversary of the grant date, with the remaining 75% vesting in equal increments every three months over the following three years, contingent on continued employment. These grants were made under Amwell's Inducement Plan and comply with NYSE's Listed Company Manual Rule 303A.08.
Amwell (NYSE: AMWL), a leading SaaS-based healthcare platform provider, has announced its participation in the TD Cowen 24th Annual Health Care conference in Boston. Dr. Ido Schoenberg, Amwell's chairman and CEO, will engage in a fireside chat on March 4 at 9:10 a.m. ET, along with one-on-one meetings during the conference. Investors can access the audio webcast of the fireside chat through the company's investor relations website at investors.amwell.com.
Amwell (NYSE: AMWL), a provider of SaaS-based technology-enabled healthcare platform, has announced its financial results for the fourth quarter and full year 2024. The company will discuss these results during a conference call scheduled for February 12, 2025, at 5 p.m. ET. Investors can access the earnings report through Amwell's investor relations website, and a live audio webcast of the conference call will be available. A replay of the call will be accessible via webcast on the investor relations website after the event.
Amwell (NYSE: AMWL) has announced it will release its fourth quarter and full year 2024 operating results after market close on Wednesday, February 12, 2025. The company will host a conference call and webcast at 5:00 PM ET on the same day, where management will discuss the financial results and provide business updates. The earnings report and webcast will be accessible through the Investors section of Amwell's website, with a replay available for approximately 90 days at investors.amwell.com.